AR013422A1 - UN VECTOR DE EXPRESIoN REPLICABLE QUE COMPRENDE UN ÁCIDO NUCLEICO QUE CODIFICA PARA UN POLIPÉPTIDO, UNA CÉLULA HUÉSPED ANIMAL AISLADA INCAPAZ DE CONDUCIR A UN ORGANISMO COMPLETO, UN MICROORGANISMO, UN MÉTODO PARA PRODUCIR UN POLIPEPTIDO DE SEC IN N° 2, UNA PROTEíNA DE FUSIoN, UN ANTICUERPO MONOCLONA - Google Patents

UN VECTOR DE EXPRESIoN REPLICABLE QUE COMPRENDE UN ÁCIDO NUCLEICO QUE CODIFICA PARA UN POLIPÉPTIDO, UNA CÉLULA HUÉSPED ANIMAL AISLADA INCAPAZ DE CONDUCIR A UN ORGANISMO COMPLETO, UN MICROORGANISMO, UN MÉTODO PARA PRODUCIR UN POLIPEPTIDO DE SEC IN N° 2, UNA PROTEíNA DE FUSIoN, UN ANTICUERPO MONOCLONA

Info

Publication number
AR013422A1
AR013422A1 ARP980104054A ARP980104054A AR013422A1 AR 013422 A1 AR013422 A1 AR 013422A1 AR P980104054 A ARP980104054 A AR P980104054A AR P980104054 A ARP980104054 A AR P980104054A AR 013422 A1 AR013422 A1 AR 013422A1
Authority
AR
Argentina
Prior art keywords
propute
polypeptide
lead
nucleic acid
complete
Prior art date
Application number
ARP980104054A
Other languages
English (en)
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL12155497A external-priority patent/IL121554A0/xx
Priority claimed from IL12163997A external-priority patent/IL121639A0/xx
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of AR013422A1 publication Critical patent/AR013422A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/834—Urine; urinary system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)

Abstract

Se proveen proteínas de enlace a interleucina-18 que son capaces de enlazarse a IL-18 y/o modular y/o bloquear la actividad de IL-18. También sepresentan métodos para su aislacion y produccion recombinante, ADNs que las codifican,vectore s de ADN que las expresan, vectores utiles para su expresionen humanos y otros mamíferos, anticuerpos contra las mismas.
ARP980104054A 1997-08-14 1998-08-14 UN VECTOR DE EXPRESIoN REPLICABLE QUE COMPRENDE UN ÁCIDO NUCLEICO QUE CODIFICA PARA UN POLIPÉPTIDO, UNA CÉLULA HUÉSPED ANIMAL AISLADA INCAPAZ DE CONDUCIR A UN ORGANISMO COMPLETO, UN MICROORGANISMO, UN MÉTODO PARA PRODUCIR UN POLIPEPTIDO DE SEC IN N° 2, UNA PROTEíNA DE FUSIoN, UN ANTICUERPO MONOCLONA AR013422A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IL12155497A IL121554A0 (en) 1997-08-14 1997-08-14 Interleukin-18 binding proteins their preparation and use
IL12163997A IL121639A0 (en) 1997-08-14 1997-08-27 Interleukin-18 binding proteins their preparation and use
IL12186097A IL121860A0 (en) 1997-08-14 1997-09-29 Interleukin-18 binding proteins their preparation and use
IL12213497A IL122134A0 (en) 1997-08-14 1997-11-06 Interleukin-18 binding proteins their preparation and use
IL12546398A IL125463A0 (en) 1997-08-14 1998-07-22 Interleukin-18 binding proteins their preparation and use

Publications (1)

Publication Number Publication Date
AR013422A1 true AR013422A1 (es) 2000-12-27

Family

ID=27517687

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP980104054A AR013422A1 (es) 1997-08-14 1998-08-14 UN VECTOR DE EXPRESIoN REPLICABLE QUE COMPRENDE UN ÁCIDO NUCLEICO QUE CODIFICA PARA UN POLIPÉPTIDO, UNA CÉLULA HUÉSPED ANIMAL AISLADA INCAPAZ DE CONDUCIR A UN ORGANISMO COMPLETO, UN MICROORGANISMO, UN MÉTODO PARA PRODUCIR UN POLIPEPTIDO DE SEC IN N° 2, UNA PROTEíNA DE FUSIoN, UN ANTICUERPO MONOCLONA
ARP070104104A AR062867A2 (es) 1997-08-14 2007-09-17 Proteinas de enlace a interleuquina -18, (il- 18bp), secuencias de adn que codifican para la il -18 bp, secuencias de adnc, un vehiculo de expresion replicable, celula huesped, un proceso para su produccion y aislacion, anticuerpos, composiciones farmaceuticas, el uso de dichas composiciones para la

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP070104104A AR062867A2 (es) 1997-08-14 2007-09-17 Proteinas de enlace a interleuquina -18, (il- 18bp), secuencias de adn que codifican para la il -18 bp, secuencias de adnc, un vehiculo de expresion replicable, celula huesped, un proceso para su produccion y aislacion, anticuerpos, composiciones farmaceuticas, el uso de dichas composiciones para la

Country Status (29)

Country Link
US (4) US6605280B1 (es)
EP (1) EP1003781B1 (es)
JP (1) JP4272348B2 (es)
KR (1) KR100687388B1 (es)
CN (1) CN1243021C (es)
AR (2) AR013422A1 (es)
AT (1) ATE443719T1 (es)
AU (1) AU755794B2 (es)
BG (1) BG65519B1 (es)
BR (1) BRPI9811940B8 (es)
CA (1) CA2298855C (es)
CY (1) CY1109664T1 (es)
CZ (1) CZ300818B6 (es)
DE (2) DE69841175D1 (es)
DK (1) DK1003781T3 (es)
EA (1) EA003675B1 (es)
EE (1) EE05538B1 (es)
ES (1) ES2149149T3 (es)
HK (1) HK1028773A1 (es)
HU (1) HU226698B1 (es)
IL (5) IL121860A0 (es)
NO (1) NO327240B1 (es)
NZ (1) NZ502392A (es)
PL (1) PL206070B1 (es)
PT (1) PT1003781E (es)
SI (1) SI1003781T1 (es)
SK (1) SK287194B6 (es)
UA (1) UA75862C2 (es)
WO (1) WO1999009063A1 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393663B2 (en) * 1997-08-01 2008-07-01 Serono Genetics Institute S.A. Expressed sequence tags and encoded human proteins
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
BR9816013A (pt) * 1998-09-01 2003-01-21 Hayashibara Biochem Lab Proteìna de ligação de interleucina-18
AR022952A1 (es) 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
IL131047A0 (en) * 1999-07-22 2001-01-28 Yeda Res & Dev Use of il-18 inhibitors
CA2324168A1 (en) * 1999-11-16 2001-05-16 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Antibody specific to interleukin 18 precursor
KR20110032012A (ko) 2000-02-10 2011-03-29 아보트 러보러터리즈 사람 인터류킨-１８에 결합하는 항체 및 이를 제조하고 사용하는 방법
KR20070087256A (ko) * 2000-02-21 2007-08-27 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. Ｉｌ-18 저해물질의 용도
AU2005211606B2 (en) * 2000-05-05 2007-02-22 Inserm - Institut National De La Sante Et De La Recherche Medicale Use of IL-18 inhibitors for the treatment and/or prevention of atherosclerosis
AU2001267390B2 (en) * 2000-05-05 2005-09-22 Inserm - Institut National De La Sante Et De La Recherche Medicale Use of IL-18 inhibitors for the treatment and/or prevention of atherosclerosis
AU1174402A (en) 2000-10-11 2002-04-22 Viron Therapeutics Inc Nucleic acid molecules and polypeptides for immune modulation
US7718368B2 (en) * 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
EA010180B1 (ru) * 2001-01-29 2008-06-30 Лаборатуар Сероно Са Применение ингибитора il-18 для приготовления лекарственного средства для лечения и/или профилактики кардиомиопатии
DK1425028T3 (da) * 2001-05-16 2010-03-01 Yeda Res & Dev Anvendelse af IL-18 inhibitorer til behandling eller forebyggelse af sepsis
PL216228B1 (pl) * 2001-05-25 2014-03-31 Ares Trading Sa Zastosowanie białka wiążącego IL-18
ES2907826T3 (es) 2001-06-26 2022-04-26 Amgen Inc Anticuerpos para OPGL
UA78516C2 (en) * 2001-08-10 2007-04-10 Applied Research Systems Use of inhibitors of il-18 for treatment and/or prevention of hypersensitivity disorders, and in particular of delayed-type hypersensitivity
US9592267B2 (en) * 2002-03-22 2017-03-14 Merck Serono Sa Use of IL-18BP for treatment of peripheral vascular diseases
PL376536A1 (pl) 2002-08-28 2006-01-09 Immunex Corporation Kompozycje i sposoby leczenia chorób układu sercowo-naczyniowego
KR101015682B1 (ko) * 2002-10-08 2011-02-22 아레스 트레이딩 에스.에이. Ｉｌ-18ｂｐ에 결합할 수 있고 제 2 사이토킨의 활성을저해할 수 있는 사이토킨의 용도
IL152232A0 (en) 2002-10-10 2003-05-29 Yeda Res & Dev Promoter to il-18bp, its preparation and use
EP1621616A4 (en) 2003-04-30 2007-07-04 Japan Science & Tech Agency ANTIHUMAN INTERLEUKIN-18 HUMAN ANTIBODY, FRAGMENT THEREOF AND METHOD OF USING SAME
PT1622939E (pt) 2003-05-13 2012-03-28 Merck Serono Sa Variantes ativas da proteína de ligação à il-18 e suas utilizações médicas
EP1689777B1 (en) * 2003-11-05 2007-04-25 Ares Trading S.A. Process for the purification of il-18 binding protein
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
JP4979385B2 (ja) 2003-11-12 2012-07-18 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト 腫瘍壊死因子αの調節のための組成物及び方法
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
IL159670A0 (en) * 2003-12-31 2004-06-01 Yeda Res & Dev Use of il-18 binding protein in inflammations
AU2005217154B2 (en) * 2004-03-01 2010-02-18 Ares Trading S.A. Use of a serum-free cell culture medium for the production of IL-18BP in mammalian cells
WO2005097998A2 (en) * 2004-03-31 2005-10-20 Regeneron Pharmaceuticals, Inc. Il-18 specific polypeptides and therapeutic uses thereof
US7439336B2 (en) 2004-06-29 2008-10-21 Ares Trading S.A. Process for the purification of IL-18 binding protein
EP2267024B1 (en) 2005-06-03 2012-05-09 Ares Trading S.A. Production of recombinant Il-18 binding protein
PT1888100E (pt) * 2005-06-03 2011-12-15 Merck Serono Sa Uso de isoformas de il-18bp para o tratamento e/ou prevenção de doenças inflamatórias neurológicas
CA2610804C (en) 2005-06-10 2013-11-19 Ares Trading S.A. Process for the purification of il-18 binding protein
CN101003812B (zh) * 2006-01-17 2011-01-05 温州医学院 一种用于制备重组人egf-il18融合蛋白的方法
NZ572565A (en) 2006-05-25 2011-04-29 Glaxo Group Ltd Modified humanised anti-interleukin-18 antibodies
WO2010040736A2 (en) * 2008-10-07 2010-04-15 Ablynx Nv Amino acid sequences directed against il18 and/or the il-18 receptor and polypeptides comprising the same for the treatment of diseases and/or disorders associated with il-18 mediated signaling
CA2897067A1 (en) * 2013-01-02 2014-07-10 Wilsa, Inc. Method and apparatus for conditioning fluids
ES2892923T3 (es) 2013-09-05 2022-02-07 Ab2 Bio Sa Proteína de unión a IL-18 (IL-18BP) en enfermedades inflamatorias
JP7274259B2 (ja) * 2015-03-05 2023-05-16 エイビー２ バイオ ソシエテアノニム 炎症性疾患におけるｉｌ－１８結合タンパク質（ｉｌ－１８ｂｐ）および抗体
EP3943097A1 (en) 2020-07-24 2022-01-26 AB2 Bio SA Car-t cell therapy
CN117279950A (zh) * 2022-01-28 2023-12-22 和径医药科技（上海）有限公司 一种靶向il-18bp的抗体及其应用
AU2023236289A1 (en) * 2022-03-15 2024-08-15 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
CN114605521A (zh) * 2022-04-06 2022-06-10 内蒙古农业大学 一种细胞免疫调节蛋白及其应用
CN114891125B (zh) * 2022-06-16 2023-04-11 广东医科大学 一种长效重组白细胞介素-18结合蛋白及其生产方法与应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985863A (en) * 1996-09-12 1999-11-16 Vertex Pharmaceuticals, Inc. Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor
GB9214857D0 (en) * 1992-07-13 1992-08-26 Medical Res Council Human nucleic acid fragments and their use
US5744451A (en) 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
US5776731A (en) 1996-02-21 1998-07-07 Immunex Corporation DNA encoding type-I interleukin-I receptor-like protein designated 2F1
DK0936923T3 (da) 1996-11-15 2004-04-26 Kennedy Inst Of Rheumatology Undertrykkelse af TNFalpha og IL-12 ved terapi
DE69736984T2 (de) 1996-12-06 2007-09-13 Vertex Pharmaceuticals Inc., Cambridge Inhibitoren des interleukin-1-beta konvertierenden enzyms
US7141393B2 (en) 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
US6087116A (en) * 1997-03-12 2000-07-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18 (IL-18) receptor polypeptides and their uses
TR199902615T2 (xx) 1997-03-18 2000-03-21 Basf Aktiengesellschaft Kortikosteroidlere verilen cevab�n mod�lasyonuna y�nelik metodlar ve kompozisyonlar.
ES2266693T3 (es) 1997-08-01 2007-03-01 Serono Genetics Institute S.A. Ests 5' para proteinas secretadas expresadas en varios tejidos.
EP1378571B1 (en) 1997-08-01 2011-01-12 Merck Serono Biodevelopment 5' ESTs for secreted proteins expressed in various tissues
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
PT1421956E (pt) 1998-04-28 2007-07-13 Serono Lab Processo para a ligação por passos de polietileno glicol ( peg ) a um polipéptido
CA2276216A1 (en) 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
BR9816013A (pt) 1998-09-01 2003-01-21 Hayashibara Biochem Lab Proteìna de ligação de interleucina-18
AR022952A1 (es) 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
WO2001003719A2 (en) 1999-07-09 2001-01-18 Amgen Inc. Combination therapy for conditions leading to bone loss
AU7127600A (en) 1999-09-17 2001-04-17 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids

Also Published As

Publication number Publication date
CY1109664T1 (el) 2014-08-13
UA75862C2 (uk) 2006-06-15
EP1003781B1 (en) 2009-09-23
ES2149149T1 (es) 2000-11-01
IL121860A0 (en) 1998-02-22
BG104149A (en) 2000-08-31
IL122134A0 (en) 1998-04-05
BRPI9811940B1 (pt) 2011-10-04
JP2001514876A (ja) 2001-09-18
PL338647A1 (en) 2000-11-06
NO327240B1 (no) 2009-05-18
DE1003781T1 (de) 2001-01-11
HUP0003533A2 (hu) 2001-01-29
IL134523A0 (en) 2001-04-30
SK1762000A3 (en) 2000-09-12
NO20000700L (no) 2000-04-14
EA003675B1 (ru) 2003-08-28
CN1243021C (zh) 2006-02-22
CN1267307A (zh) 2000-09-20
EE05538B1 (et) 2012-04-16
EE200000073A (es) 2000-10-16
HK1028773A1 (en) 2001-03-02
NZ502392A (en) 2002-12-20
DE69841175D1 (de) 2009-11-05
WO1999009063A1 (en) 1999-02-25
KR100687388B1 (ko) 2007-02-26
BG65519B1 (bg) 2008-10-31
US20060154294A1 (en) 2006-07-13
PL206070B1 (pl) 2010-06-30
SI1003781T1 (sl) 2009-12-31
NO20000700D0 (no) 2000-02-11
SK287194B6 (sk) 2010-03-08
AU8746098A (en) 1999-03-08
HU226698B1 (en) 2009-07-28
HUP0003533A3 (en) 2003-08-28
EA200000216A1 (ru) 2000-08-28
EP1003781A1 (en) 2000-05-31
AU755794B2 (en) 2002-12-19
CZ2000490A3 (cs) 2000-08-16
CZ300818B6 (cs) 2009-08-19
AR062867A2 (es) 2008-12-10
IL125463A0 (en) 1999-03-12
US7799541B2 (en) 2010-09-21
JP4272348B2 (ja) 2009-06-03
ES2149149T3 (es) 2009-12-01
US6605280B1 (en) 2003-08-12
US20100010200A1 (en) 2010-01-14
ATE443719T1 (de) 2009-10-15
KR20010022900A (ko) 2001-03-26
PT1003781E (pt) 2009-10-26
CA2298855A1 (en) 1999-02-25
IL134523A (en) 2011-09-27
US20040037829A1 (en) 2004-02-26
US8436148B2 (en) 2013-05-07
BRPI9811940B8 (pt) 2021-07-06
BRPI9811940A (pt) 2000-09-05
US7101689B2 (en) 2006-09-05
DK1003781T3 (da) 2010-01-25
CA2298855C (en) 2014-05-27

Similar Documents

Publication Publication Date Title
AR013422A1 (es) UN VECTOR DE EXPRESIoN REPLICABLE QUE COMPRENDE UN ÁCIDO NUCLEICO QUE CODIFICA PARA UN POLIPÉPTIDO, UNA CÉLULA HUÉSPED ANIMAL AISLADA INCAPAZ DE CONDUCIR A UN ORGANISMO COMPLETO, UN MICROORGANISMO, UN MÉTODO PARA PRODUCIR UN POLIPEPTIDO DE SEC IN N° 2, UNA PROTEíNA DE FUSIoN, UN ANTICUERPO MONOCLONA
ES2058238T3 (es) Estructuras adn con contenido de una secuencia conductora de factor alfa de kluyveromyces para dirigir la secrecion de polipeptidos heterologos.
ES2122955T3 (es) Adn que codifica proteinas que se unen a la il-1 humana.
ATE178652T1 (de) Verbessertes verfahren zur herstellung von endotoxinbindungsproteinen
MX9700007A (es) Anticuerpos que fijan las proteinas del intestino de los insectos y su uso.
NZ503343A (en) Secreted and transmembrane polypeptides and use to induce apoptosis of tumour cells
ATE353362T1 (de) Neuartige ctla4/cd28 liganden und deren anwendungen
AP9901541A0 (en) Broad-spectrum delta-endotoxins.
ATE140731T1 (de) Plasmidvektor mit pectatlyase-signalsequenz
ES508813A0 (es) Metodo de expresion de un gen codificador de un polipeptido util en una coagulacion de la leche.
ATE313633T1 (de) Expressionsvektoren die für bispezifische proteine kodieren, und verfahren zur herstellung von biologisch-aktiven bispezifischen fusionsproteine in zellen von säugertieren
ATE393222T1 (de) Dcr3 polypeptid, ein tnfr homolog
ES2088858T3 (es) Proteina interleuquina-4 que tiene actividad de factor de crecimiento de celulas b(bcgf) y de factor de crecimiento de celulas t(tcgf) en celulas humanas (interleuquina-4 humana).
HUP0001650A2 (hu) Javított expressziós vektorok
DK13788D0 (da) Fremgangsmaade til fremstilling af et polypeptid
DE60033293D1 (de) Neue b7-4 moleküle und deren verwendungen
DK1218504T3 (da) GL50 molekyler og anvendelser deraf
DK111183A (da) Polypeptid omfattende aminosyresekvensen af et dyreinterferon, dna-sekvens, der koder for polypeptidet, replicerbart udtrykkelsesmedium, som kan udtrykke dna-sekvensen, og fremgangsmaade til fremstilling af polypeptidet
KR100468977B1 (ko) 분비 및 막횡단 폴리펩티드, 및 이를 코딩하는 핵산
NO860421L (no) Sammensmeltet gen som koder for et hybridprotein.
ATE353964T1 (de) Crsp-proteine (cystein-reiche, sekretierte proteine), die dafür kodierenden nukleinsäuren und ihre verwendungen
DE60137829D1 (de) Menschliche stra6 polypeptide
DE3877136D1 (de) Rekombinantes histidinreiches protein von plasmodium falciparum, seine herstellung und verwendung.
ES2170051T3 (es) Procedimiento para la produccion de proteinas utilizando proteinas fusionadas de tipo cks.
DE69932644D1 (de) Menschliches Protein mit in vitro antiproliferativer Aktivität.

Legal Events

Date Code Title Description
FG Grant, registration